Проблема резистентных депрессивных расстройств в наркологической практике
Рекомендуемое оформление библиографической ссылки:
Полянский Д.А., Кожинова Т.А., Шеин В.В. Проблема резистентных депрессивных расстройств в наркологической практике // Российский психиатрический журнал. 2021. №1. С. 73-81.
В научном обзоре с целью изучения проблемы затяжных и резистентных к терапии аффективных расстройств депрессивного регистра при болезнях зависимости представлена информация и результаты исследований отечественных и зарубежных авторов по данному вопросу. Отсутствие у определённого процента пациентов с депрессивными расстройствами на фоне болезней зависимости адекватного лечения с помощью доступных методов терапии, а также отсутствие амбулаторного сопровождения, позволяющего подобрать оптимальное лечение, приводят со временем к развитию у пациентов резистентности к терапии. Актуальность проблемы изучения резистентных депрессий в наркологической практике несомненна, в связи с этим существует острая потребность в новых подходах и методах лечения для её решения.
Ключевые слова депрессивное расстройство; болезни зависимости; резистентность к терапии
1. VOZ. Informacionnyj bjulleten' № 369, Fevral' 2017 g. URL: https://www.who.int/ru/news-room/fact-sheets/detail/depression (accessed: 08.02.2021). (In Russ.) 2. Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. DOI: https://doi.org/10.1038/nrdp.2016.65; PMID: 27629598 3. Balanza-Martinez V, Crespo-Facorro B, Gonzalez-Pinto A, Vieta E. Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. Front Physiol. 2015;6:108. DOI: https://doi.org/10.3389/fphys.2015.00108; PMID: 25904869 4. Rozin AI, Roshchina OV, Peshkovskaya AG, Belokrylov II. [Comorbid combinations of alcohol dependence and depressive disorders]. Sibirskij vestnik psihiatrii i narkologii [Siberian Herald of Psychiatry and Addiction Psychiatry]. 2018;4(101):40–5. (In Russ.) DOI: https://doi.org/10.26617/1810-3111-2018-4(101)-40-45 5. Shlemina IV. Klinika i terapiya shizotipicheskogo rasstroistva (maloprogredientnoi shizofrenii), sochetayushchegosya s alkogolizmom. Psihicheskoezdorov'e. 2009;(5):41–8. (In Russ.) 6. Rehm J, Taylor B, Room R. Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev. 2006;25(6):503–13. DOI: https://doi.org/10.1080/09595230600944453; PMID: 17132570 7. Currie SR, Patten SB, Williams JV, et al. Comorbidity of major depression with substance use disorders. Can J Psychiatry. 2005;50(10):660–6. DOI: https://doi.org/10.1177/070674370505001013; PMID: 16276858 8. Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21(1):14–8. DOI: https://doi.org/10.1097/YCO.0b013e3282f32408; PMID: 18281835 9. Abraham HD, Fava M. Order of onset of substance abuse and depression in a sample of depressed outpatients. Compr Psychiatry. 1999;40(1):44–50. DOI: https://doi.org/10.1016/s0010-440x(99)90076-7; PMID: 9924877 10. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730–7. DOI: https://doi.org/10.1016/j.biopsych.2004.06.034; РMID: 15556117 11. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906–14. DOI: https://doi.org/10.1111/j.1360-0443.2010.03351.x; PMID: 21382111 12. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15):1887–96. DOI: https://doi.org/10.1001/jama.291.15.1887; PMID: 15100209 13. Nunes EV, Levin FR. Treating depression in substance abusers. Curr Psychiatry Rep. 2006;8(5):363–70. DOI: https://doi.org/10.1007/s11920-006-0037-8 14. Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996;37(6):518–22. DOI: https://doi.org/10.1016/S0033-3182(96)71515-3; PMID: 8942202 15. Geschwind DH, Flint J. Genetics and genomics of psychiatric disease. Science. 2015;349(6255):1489–94. DOI: https://doi.org/10.1126/science.aaa8954; PMID: 26404826 16. Akil H, Gordon J, Hen R, et al. Treatment resistant depression: A multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–88. DOI: https://doi.org/10.1016/j.neubiorev.2017.08.019; PMID: 28859997 17. Pougovkina OD, Kholmogorova AB, Tsukarzi EE, et al. [Dynamics of cognitive functioning in patients with resistant depression treated with ECT and the cyclical transcranial magnetic stimulation]. Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2006;16(2):47–51. (In Russ.) 18. Ballas C, Staab JP, Evans DL. Strategies for treatment-resistant depression. Psychopharmacol Bull. 2002;36(4):39–62. PMID: 12858144 19. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(13):23–9. PMID: 9402916 20. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull. 1990;26(4):429–60. PMID: 2087539 21. Bondar' VV. Terapevticheski rezistentnye endogennye depressii (klinika, tipologiya, voprosy patogeneza i lecheniya) [PhD thesis]. [Moscow (Russia)]: Rossiiskaya akademiya med. nauk. Nauch. Tsentr psikhicheskogo zdorov'ya [Russian Academy of Medical Sciences. Mental Health Science Center]; 1992. 22 p. (In Russ.) 22. Lubov EB, Sarkisyan GR. Depressivnie rasstroystva: pharmakon-epidemicheskie I kliniko-ekonomicheskie aspekti. Psichiatria i psichofarmakoterapia [Psychiatry and psychopharmacotherapy]. 2006;2(16):93–100. (In Russ.) 23. Thase ME, Schwartz TL. Choosing medications for treatment-resistant depression based on mechanism of action. J Clin Psychiatry. 2015;76(6):720–7. DOI: https://doi.org/10.4088/JCP.14052ah2c; PMID: 26132673 24. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–7. DOI: https://doi.org/10.4088/jcp.v65n0309; PMID: 15096073 25. Bikov UV. Resistentnie k terapii depressii. Stavropol; 2009. 77 p. (In Russ.) 26. Vovin RY. Terapevticheskaya rezistentnost' pri shizofrenii i affektivnykh psikhozakh. Leningrad; 1975. р. 5–13. (In Russ.) 27. Mosolov SN. Rezistentost` k psikhofarmakoterapii. Psichiatria i psichofarmakoterapia [Psychiatry and psychopharmacotherapy]. 2004;2:128–32. (In Russ.) 28. Mosolov SN. Klinicheskoe primenenie sovremenny`x antidepressantov. Saint Petersburg; 1995. 568 p. (In Russ.) 29. Mazo GE, Neznanov NG. Terapevticheski rezistentnye depressii. Saint Petersburg; 2012. 448 p. (In Russ.) 30. Trivedi MH. Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry. 2003;15:59–70. DOI: https://doi.org/10.1023/A:1023232727217; PMID: 12839433 31. Avrutsky GY, Neduva AA. Lechenie psikhicheskikh bol'nykh: Rukovodstvo dlya vrachei. Moscow; 1988. 496 p. (In Russ.) 32. Smulevich AB. Depressii pri somaticheskih I psichicheskich zabolevaniach. Moscow; 2007. 432 р. (In Russ.) 33. Mazo GE, Gorbachev SE, Petrova NN. Terapevticheski rezistentnye depressii: sovremennye podkhody k diagnostike i lecheniyu. Vestnik Sankt-Peterburgskogo Universiteta [Vestniks of Saint Petersburg University]. 2008;2(11):87–96. (In Russ.) 34. Podkorytov VS, Chaika UU. Depressia i rezistentnost`. Zhurnal psichiatrii I medinskoy psichologii [Journal of Psychiatry and Medical Psychology]. 2002;1:118–24. (In Russ.) 35. Vertogradova OP, Petoukhov VV. Zatyazhnie depressii (zakonomernosti fjrmirovania, prognoz, terapiya). Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2005;4(15):18–23. (In Russ.) 36. Minutko VL. Depressia. Moscow; 2006. 326 p. (In Russ.) 37. Arushanyan AB. Chronofarmakologia: narubezhe vekov. Stavropol; 2005. 576 p. (In Russ.) 38. Mosolov SN. Klinicheskoe primenenie sovremennih antidepressantov. Russkiy medicinskiy zhurnal [Russian Medical Journal]. 2005;12(13):852–7. (In Russ.) 39. Smulevich AB. Depressia kak obschemedicinskaya problema: voprosi kliniki I terapii. Psichiatria i psichofarmakoterapia [Psychiatry and psychopharmacotherapy]. 2006;3(8):4–10. (In Russ.) 40. Vovin RY, Axenova LI, Kune GE. Farmakoterapevticheskie osnovi reabilitacii psihicheskih bol`nih. Мoscow; 1989. р. 151–81. (In Russ.) 41. Puchkov II. Otkazy ot psikhofarmakoterapii u bol'nykh s nepsikhoticheskimi depressivnymi rasstroistvami [PhD thesis]. [Moscow(Russia)]: Gosudarstvennyi nauchnyi tsentr sotsial'noi i sudebnoi psikhiatrii im. V.P. Serbskogo MZ RF [State Scientific Center for Social and Forensic Psychiatry im. V. Serbsky Ministry of Health of the Russian Federation]; 2005. 28 p. (In Russ.) 42. Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 2011;30:22–60. DOI: https://doi.org/10.1159/000324065; PMID: 21508625 43. Russel J. Emotion, core affect, and psychological construction. Cogn Emot. 2009;23(7):1259–83. DOI: https://doi.org/10.1080/02699930902809375 44. Ekkekakis P. The Measurement of Affect, Mood, and Emotion: A Guide for Health-Behavioral Research. Cambridge, UK, New York: Cambridge University Press; 2013. 226 p. 45. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci. 2008;10(3):291–9. DOI: https://doi.org/10.31887/DCNS.2008.10.3/pgorwood; PMID: 18979942 46. Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149–64. DOI: https://doi.org/10.2147/NDT.S111818; PMID: 27601909 47. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):68–77. DOI: https://doi.org/10.1016/j.tins.2011.11.005; PMID: 22177980 48. Snaith RP, Hamilton M, Morley S, at al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99–103. DOI: https://doi.org/10.1192/bjp.167.1.99; PMID: 7551619 49. Huhn AS, Meyer RE, Harris JD, et al. Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. Brain Res Bull. 2016;123:102–9. DOI: https://doi.org/10.1016/j.brainresbull.2015.12.004; PMID: 26711857 50. Garfield JB, Allen NB, Cheetham A, et al. Attention to pleasant stimuli in early adolescence predicts alcohol-related problems in mid-adolescence. Biol Psychol. 2015;108:43–50. DOI: https://doi.org/10.1016/j.biopsycho.2015.03.014 51. Martinotti G, Cloninger CR, Janiri L. Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. Am J Drug Alcohol Abuse. 2008;34(2):177–83. DOI: https://doi.org/10.1080/00952990701877078 52. Cook JW, Spring B, McChargue D, et al. Hedonic capacity, cigarette craving, and diminished positive mood. Nicotine Tob Res. 2004;6(1):39–47. DOI: https://doi.org/10.1080/14622200310001656849; PMID: 14982686 53. Leventhal AM, Waters AJ, Kahler CW, et al. Relations between anhedonia and smoking motivation. Nicotine Tob Res. 2009;11(9):1047–54. DOI: https://doi.org/10.1093/ntr/ntp098; PMID: 19571250 54. Aalto S, Ingman K, Alakurtti K, et al. Intravenous ethanol increases dopamine release in the ventral striatum in humans: PET study using bolus-plus-infusion administration of [(11)C]raclopride. J Cereb Blood Flow Metab. 2015;35(3):424–31. DOI: https://doi.org/10.1038/jcbfm.2014.209; PMID: 25492110 55. Verdejo-Garcia A, Clark L, Verdejo-Román J, et al. Neural substrates of cognitive flexibility in cocaine and gambling addictions. Br J Psychiatry. 2015;207(2):158–64. DOI: https://doi.org/10.1192/bjp.bp.114.152223; PMID: 26045346
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10108
Метрики статей
Metrics powered by PLOS ALM